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Abstract 
Background: The recent dramatic decline in dihydroartemisinin-piperaquine (DHA-PPQ) efficacy in northwestern 
Cambodia has raised concerns about the rapid spread of piperaquine resistance just as DHA-PPQ is being introduced 
as first-line therapy in neighbouring countries.
Methods: Ex vivo parasite susceptibilities were tracked to determine the rate of progression of DHA, PPQ and meflo-
quine (MQ) resistance from sentinel sites on the Thai–Cambodian and Thai–Myanmar borders from 2010 to 2015. 
Immediate ex vivo (IEV) histidine-rich protein 2 (HRP-2) assays were used on fresh patient Plasmodium falciparum 
isolates to determine drug susceptibility profiles.
Results: IEV HRP-2 assays detected the precipitous emergence of PPQ resistance in Cambodia beginning in 2013 
when 40 % of isolates had an IC90 greater than the upper limit of prior years, and this rate doubled to 80 % by 2015. In 
contrast, Thai–Myanmar isolates from 2013 to 14 remained PPQ-sensitive, while northeastern Thai isolates appeared 
to have an intermediate resistance profile. The opposite trend was observed for MQ where Cambodian isolates 
appeared to have a modest increase in overall sensitivity during the same period, with IC50 declining to median levels 
comparable to those found in Thailand. A significant association between increased PPQ IC50 and IC90 among Cam-
bodian isolates with DHA-PPQ treatment failure was observed. Nearly all Cambodian and Thai isolates were deemed 
artemisinin resistant with a >1 % survival rate for DHA in the ring-stage assay (RSA), though there was no correlation 
among isolates to indicate cross-resistance between PPQ and artemisinins.
Conclusions: Clinical DHA-PPQ failures appear to be associated with declines in the long-acting partner drug PPQ, 
though sensitivity appears to remain largely intact for now in western Thailand. Rapid progression of PPQ resistance 
associated with DHA-PPQ treatment failures in northern Cambodia limits drugs of choice in this region, and urgently 
requires alternative therapy. The temporary re-introduction of artesunate AS-MQ is the current response to PPQ resist-
ance in this area, due to inverse MQ and PPQ resistance patterns. This will require careful monitoring for re-emergence 
of MQ resistance, and possible simultaneous resistance to all three drugs (AS, MQ and PPQ).
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Background
Artemisinin combination therapy (ACT) remains the 
most effective currently available regimen for multi-
drug-resistant falciparum malaria, and as such is key to 
reducing the global malaria burden [1, 2]. While arte-
misinin-resistant Plasmodium falciparum has emerged 
in the western provinces of Cambodia, and some neigh-
boring countries in Southeast Asia [3–6], ACT appears 
to remain clinically effective where partner drug efficacy 
is preserved. Dihydroartemisinin-piperaquine (DHA-
PPQ) has been widely adopted in the region as a first-line 
agent to treat multi-drug resistant falciparum malaria. 
In 2008, it replaced artesunate-mefloquine (AS-MQ) in 
select areas of western Cambodia due to AS-MQ treat-
ment failures [7]. In early studies, various PPQ-contain-
ing ACT showed excellent safety and tolerability with 
efficacy of 96–98 % in Cambodia [8–12], and DHA-PPQ 
was implemented as the drug of choice countrywide a 
few years later [13].
Treatment failures were detected soon after, as early 
as 2010, with PCR-corrected day-42 failure rate of 25 % 
in Pailin and 11  % in Pursat Provinces in Cambodia 
[14]. In 2013, high grade DHA-PPQ failure of 53 % was 
first reported in Oddar MeanChey province with cor-
responding increases in PPQ in  vitro IC50 higher than 
patient plasma PPQ levels during the terminal elimi-
nation phase [15–17]. Subsequent reports confirmed 
rapidly increasing DHA-PPQ failure rates in areas with 
previously documented artemisinin (ART) resistance 
[18, 19]. Despite the rapid loss of PPQ sensitivity, mul-
tiple studies detected a simultaneous decline in pfmdr1 
copy number amplification and increased in  vitro MQ 
sensitivity among PPQ-resistant isolates [15, 18, 20]. The 
resurgence in MQ sensitivity suggested that short-term 
re-introduction MQ-containing therapy or perhaps tri-
ple artemisinin combination therapy (TACT) containing 
both PPQ and MQ might be effective. While approaches 
are currently being pursued to various degrees by public 
health authorities and research organizations [18], there 
is no consensus regarding safety and resistance concerns 
related to the use of TACT [21].
To address this growing public health crisis, inten-
sive monitoring of drug resistance profiles remains cru-
cial information to determine appropriate alternatives 
in settings of rapidly emerging multi-drug anti-malarial 
resistance. In the absence of a known molecular PPQ 
resistance marker, field-based ex  vivo parasite drug 
susceptibility testing using fresh P. falciparum isolates 
remains a cost-effective, rapid, surveillance tool to track 
resistance [22]. Here, parasite drug susceptibilities to 
ART, PPQ and MQ between 2010 and 2015 on both sides 
of the Thai–Cambodian border, and in southwestern 
Thailand along the border with Myanmar were reported.
Methods
Study sites, protocols, and subjects
Between October 2010-April 2015, 342 P. falciparum 
mono-infections from Preah Vihear (PV) and Oddar 
MeanChey (OM) provinces in northern Cambodia, 
Pursaron (PL) village in Srisaket province in northeast 
Thailand, and Kwai River Christian Hospital (KRCH) in 
Kanchanaburi province in western Thailand were col-
lected for evaluation for PPQ, MQ and ART suscep-
tibility. All samples were collected from patients with 
uncomplicated malaria enrolled in five clinical proto-
cols (clinical trials WR1737-NCT01280162; WR1877-
NCT01849640; WR2017-NCT02052323; WR1576 and 
WR1917, both in  vitro surveillance studies). Figure  1 
shows site locations and the number of samples collected 
in each site per year. All protocols were approved by the 
Walter Reed Army Institute of Research (WRAIR) Insti-
tutional Review Board, and Cambodian National Ethics 
Committee for Health Research (NECHR), Institute for 
Development of Human Research Protection (IHRP), 
Ministry of Public Health, Thailand or Royal Thai Army 
Institutional Review Board (RTA IRB), respectively. 
All study subjects provided informed consent prior to 
participation.
Parasite susceptibility assay to PPQ and MQ
At the PV, OM and KRCH sites, blood samples were 
collected prior to treatment and tested within 2–6 h for 
ex  vivo susceptibility to PPQ and MQ using histidine 
rich protein-2 (HRP-2) ELISA to measure 50 and 90  % 
inhibitory concentration (IC50 and IC90) following pre-
viously published methods [15]. Briefly, samples with a 
parasitaemia of  ≤0.5  % were adjusted to 1.5  % haema-
tocrit in 0.5 % Albumax RPMI 1640 (containing 25 mM 
HEPES, 25 mM sodium bicarbonate, and 0.1 mg/mL gen-
tamycin), whereas those with  >0.5  % parasitaemia were 
diluted to the parasitaemia range of 0.2–0.5  % by add-
ing 50 % haematocrit human O+ red blood cells in 10 % 
serum-RPMI 1640 and adjusted to a 1.5 % haematocrit in 
0.5 % Albumax RPMI 1640 prior to adding to dried drug-
coated plates. Parasites were then incubated for 72  h at 
37 °C in a candle jar, after which plates were frozen and 
later thawed for analysis of growth inhibition using the 
HRP-2 ELISA. Due to limited amount of patient blood, 
ex vivo assay was performed as a singlet experiment. At 
the PL site, patient blood samples were cryopreserved in 
a glycerol mixed solution, then shipped to the AFRIMS 
laboratory in Bangkok to establish in  vitro culture, and 
then tested for drug susceptibility as described previ-
ously [22]. Briefly, synchronized cultures with  ≥90  % 
ring forms were diluted to 0.5 % parasitaemia with 1.5 % 
haematocrit in 0.5  % Albumax RPMI 1640, and trans-
ferred to dried drug-coated plates. Plates were incubated 
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at 37 °C with 5 % CO2, 5 % O2 and 90 % N2 for 72 h. Assay 
was done for 3–5 replicates experiments and averaged 
values were reported. Parasite growth inhibition was 
assessed using the HRP-2 ELISA. As an assay benchmark, 
the culture of reference P. falciparum W2 were tested for 
in  vitro drug susceptibility as described above. All test 
drugs were provided by the WRAIR (Silver Spring, MD, 
USA). MQ and PPQ were dissolved in 70 % ethanol and 
0.5 % lactic acid in distilled water to make 1 mg/mL stock 
solutions, respectively. Details for preparing drug coated 
plates was described previously [23].
Parasite growth after 72  h was assessed by HRP-2 
ELISA. HRP-2 optical density (OD) readings were plot-




Number of samples per year 
Total 
2010 2011 2012 2013 2014 2015 
Cambodia 
PV - 39 - - - - 39 
OM  20 7 9 98 85 35 254 
Thailand 
KRCH - - - 8 14 - 22 
PL - - - 22 5 - 27* 
Fig. 1 Sentinel sites for Plasmodium falciparum isolate collection 2010–2015. The map shows location of isolate collection sites: Preah Vihear (PV) 
and Oddar MeanChey (OM) provinces in Cambodia, the Kwai River Christian Hospital (KRCH) in Kanchanaburi province, and Pursaron (PL) village 
in Srisaket province, Thailand. Dot patterns denote collection provinces; colour shading indicates regional district areas, respectively, with individual 
health centres indicated by a plus sign. The Table includes collected isolates per site. Asterisk all samples from PV, OM and KRCH were tested fresh 
using the IEV assay. The 27 isolates collected from PL were initially cryopreserved; only 14 could be recovered from cryopreservation and main-
tained in culture to be tested for in vitro drug susceptibility
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estimated by non-linear regression analysis using the 
Graph-Pad Prism version 6.0 (GraphPad Software, Inc.-, 
San Diego, CA, USA). PPQ and MQ concentrations in 
the assay ranged from 0.9 to 674 nM and 0.3 to 200 nM, 
respectively, as well as a drug-free control to assess nor-
mal parasite growth. Starting in 2013, there were evi-
dences that field isolates were able to grow in extremely 
high PPQ concentrations, requiring maximum concen-
trations as high as 53,905  nM in order to obtain inter-
pretable drug susceptibility curves. This was far higher 
than the standard maximum PPQ level used (674  nM). 
Therefore, since 2014, a serial dilution range to achieve 
higher maximum PPQ concentrations (3.4–53,905  nM) 
was used in addition to the standard dilutions to ensure 
accurate inhibitory concentrations could be determined. 
In an attempt to estimate PPQ IC50 and IC90 of reduced 
susceptible isolates from 2013 tested on standard PPQ 
dilution range (0.9 to 674 nM), reanalysis was done to fit 
‘zero-growth’ OD values at the extrapolated PPQ concen-
tration of 53,905  nM to better estimate accurate dose–
response curves [24].
Ring‑stage survival assay (RSA) for ART susceptibility
A portion of Cambodian and northeast Thai isolates was 
tested for sensitivity to ARTs using a ring-stage survival 
assay (RSA). Cambodian samples were tested for ex vivo 
RSA within 2–6 h of phlebotomy, without prior culture 
adaptation or parasite synchronization steps following 
published methods [25]. Briefly, samples with parasitae-
mias of ≤1 % were adjusted to 2 % haematocrit in culture 
media (0.5 % Albumax RPMI 1640 with 2.5 % AB serum), 
and cultured in a 48-well microplate with 700 nM DHA 
and 0.1  % DMSO in separate wells for growth control. 
Samples with >1 % parasitaemia were diluted to a para-
sitaemia range of 0.5–1  % by adding 50  % haematocrit 
human O+  red blood cells in 10  % serum-RPMI 1640 
prior to adjusting to a 2 % haematocrit. The culture plate 
was then incubated for 6 h at 37 °C in a candle jar, after 
which culture medium was discarded. Cells were then 
washed, re-suspended in drug-free medium, and cultured 
for 66 h. Susceptibility to DHA was assessed microscopi-
cally on thin films by estimating the percentage of viable 
parasites, relative to control (% survival rate).
Similar methods were performed on Thai isolates, but 
instead of ex  vivo testing on clinical samples, in  vitro 
parasite culture was established for each sample and an 
in vitro RSA0–3h was performed on 0–3-h post‐invasion 
rings obtained from culture‐adapted parasites following 
published methods [25]. Briefly, parasites cultures were 
synchronized utilizing 5 % d-sorbitol and 75 % Percoll to 
obtain 0 to 3-h post‐invasion rings which were adjusted 
to 0.5–1 % parasitaemia with a 2 % haematocrit in culture 
media. The following processes were performed as an 
ex vivo RSA, but parasites were cultured with mixed gas 
(5 % CO2, 5 % O2 and 90 % N2), instead of using a candle 
jar. As quality controls for the assay, the RSA0–3h was also 
performed on P. falciparum reference clones W2, IPC-
4884 and IPC-5202 (Malaria Research & Reference Rea-
gent Resource, Manassas, Vermont, USA) to ensure an 
acceptable range of % survival rate was attained against 
these reference clones.
Statistical analysis
Statistical analysis was performed using Graph-Pad 
Prism version 6.0 (GraphPad Software, Inc, San Diego, 
CA, USA). Parasite drug susceptibilities were expressed 
as median IC50s and IC90s for all isolates. Differences in 
susceptibility between groups were determined using 
non-parametric Mann–Whitney or Kruskal–Wallis tests 
and multiple comparison tests as appropriate. Correla-
tions between PPQ ICs and % survival rate in the pres-
ence of DHA were analyzed by calculating Spearman’s 
correlation coefficient. In order to determine the PPQ 
susceptibility baseline, Grub’s test was used for outlier 
analysis of IC values attained from Cambodian isolates 
from 2010 to 2012 where no evidence of PPQ resistance 
was detected.
Results
HRP‑2 dose response curves of Plasmodium falciparum 
isolates reveals severe ex vivo PPQ resistance
In 2013, evidence of severe ex  vivo PPQ resistance not 
observed in prior years was detected in northern Cambo-
dia when parasite isolates survived exposure at maximum 
PPQ levels (675  nM) normally employed in the ex  vivo 
HRP-2 assay [24]. Since 2014, a serial dilution range to 
achieve higher maximum PPQ concentrations (3.4–
53,905  nM) was used in addition to the standard dilu-
tions to ensure accurate inhibitory concentrations could 
be determined. Figure 2 shows dose response curves for 
isolates with a range of susceptibilities based on stand-
ard PPQ dilutions (0.9–674.8  nM) compared to the 
higher concentration range (3.4–53,905  nM). For PPQ 
sensitive isolates, sigmoidal curves and reliable analysis 
were attained from both dilution ranges (Fig. 2a). How-
ever, reduced susceptibility isolates were able to grow 
in the maximum standard PPQ level (675 nM) prevent-
ing determination of accurate growth inhibition curves 
(Fig. 2b, c). Similar to a previous report [26], anomalous 
curves due to paradoxical parasite growth at high drug 
concentrations were observed in reduced susceptibility 
isolates. However, increasing maximum PPQ concentra-
tion to 53,905  nM conferred 100  % growth inhibition, 
attaining reliable dose–response curves. In an attempt 
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Standard Concentraons Increased Concentraons
PPQ (nM) HRP-2 OD PPQ (nM) HRP-2 OD
0.0 1.42 0.0 1.40
0.9 1.29 3.4 1.37
2.8 1.27 17.2 1.24
8.3 1.30 86.2 0.51
25.0 1.17 431.2 0.43
75.0 0.64 2156.2 0.43
224.9 0.46 10781.0 0.37
674.8 0.45 53905.0 0.32
Standard Concentraons Increased Concentraons
PPQ (nM) HRP-2 OD PPQ (nM) HRP-2 OD
0.0 1.51 0.0 1.51
0.9 1.56 3.4 1.50
2.8 1.40 17.2 1.51
8.3 1.51 86.2 1.08*
25.0 1.53 431.2 1.25
75.0 1.33 2156.2 0.85
224.9 1.40 10781.0 0.61
674.8 1.26 53905.0 0.55
Standard Concentraons Increased Concentraons
PPQ (nM) HRP-2 OD PPQ (nM) HRP-2 OD
0.0 1.40 0.0 1.38
0.9 1.23 3.4 1.39
2.8 1.28 17.2 1.24
8.3 1.33 86.2 0.76*
25.0 1.31 431.2 0.96
75.0 0.90 2156.2 0.77
224.9 1.18 10781.0 0.49
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Fig. 2 Representative dose response curves for Plasmodium falciparum isolates with severely reduced PPQ sensitivity. PPQ dose–response curves of 
P. falciparum isolates with a range of susceptibility. a is a PPQ-sensitive isolate (OM-476), while b and c are PPQ-resistant isolates (OM-478, OM-489). 
% parasite growth was plotted against log [PPQ concentration] using the standard PPQ concentration range from 0 to 674.8 nM (black) and an 
increased concentration range from 0 to 53,905 nM (blue), with IC50 for each indicated. Filled symbols represent outlier values excluded from curve 
fitting. Tables present HRP-2 OD values attained for individual isolates at each concentration range, while asterisk indicates values excluded prior to 
curve fitting
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to estimate PPQ IC50 and IC90 in these isolates, dose 
response curves were interpolated by excluding outliers 
to yield best-fit models (Fig. 2b, c).
Plasmodium falciparum susceptibility to PPQ and MQ 
from 2010 to 2015
Of 315 P. falciparum isolates tested using the ex  vivo 
HRP-2 assay, IC results were evaluable in 222 isolates 
for PPQ and 230 for MQ. The in vitro assay was success-
ful for all 14 isolates recovered among 27 cryopreserved 
samples. Figure 3a and b show PPQ IC50 and IC90 for P. 
falciparum isolates collected from Cambodia and Thai-
land from 2010 to 2015. Relative to a PPQ-sensitive W2 
reference clone, Cambodian isolates from 2010 to 2012 
were sensitive to PPQ with median IC50 and IC90 of 
17–22 nM, and 41–60 nM, respectively. The emergence 
of PPQ resistance was detected in OM, Cambodia begin-
ning in 2013, with parasite isolates surviving exposure 
to maximum tested PPQ levels (674 nM) in the ex vivo 
assay, with 18 and 40 % of isolates exceeding prior year 
baselines (IC50 > 69 nM and IC90 > 160 nM). More than 
half of isolates with elevated IC90 still had an IC50 below 
prior year baselines. PPQ resistance worsened in 2014–
2015 with 70–80 % of isolates having IC90 and IC50 above 
prior baseline levels, in some cases by a thousand-fold 
over prior years.
In contrast, western Thai isolates from the same time 
period (2013–14) along the border with Myanmar were 
PPQ-sensitive with a median IC90 of 56.7 nM compara-
ble to the 2010–12 Cambodian IC90 of 60.4 nM. North-
eastern Thai isolates from 2013 to 14 collected from PL, 
roughly 100  km from Anlong Veng on the Thai–Cam-
bodian border had intermediate PPQ sensitivity with 
a median IC90 of 238.8  nM. Kruskal–Wallis and mul-
tiple comparison analysis revealed significant eleva-
tions in median Cambodian isolate PPQ IC50 and IC90 
values from 2013 to 2015, compared to prior years, as 
well as western Thai isolates from the same time period 
(P < 0.05). Modestly increased IC50/90 values for cryopre-
served, northeastern Thai isolates were not statistically 
different from ex vivo isolates from western Thailand and 
Cambodia. The opposite trend was observed for MQ sus-
ceptibility (Fig. 3c) where Cambodian isolates developed 
increased susceptibility to MQ from 2013 to 2015, with 
lower median IC50 compared to prior years and to west-
ern Thai isolates (Kruskal–Wallis test, P = 0.008).
Association of reduced PPQ susceptibility with clinical 
DHA‑PPQ treatment failure
Emergence of PPQ resistance associated with DHA-PPQ 
treatment failure was identified in clinical studies con-
ducted in Cambodia from 2010 to 13 [17]. Plasmodium 
falciparum isolates from those studies capable of ex vivo 
growth in the presence of 675 nM PPQ were more com-
mon in subjects suffering P. falciparum recrudescence 
within 42 days (43 %) than those without recrudescence 
(8 %; χ2 = 16.68; P < 0.001). Isolates from subjects with 
P. falciparum recrudescence had significantly increased 
IC50 and IC90 compared to those without recrudes-
cence, most notably for IC90, which was three-fold higher 
than in those without recrudescence (median IC50 38 
vs 26  nM, P value of Mann–Whitney U test  =  0.009; 
median IC90 of 201 vs 77  nM, P  <  0.001). Elevated IC50 
above prior baselines was more common in isolates from 
recrudescent cases (9/33 = 27 %), but was found in only 
8  % of those without recrudescence (4/48; χ2  =  5.21; 
P = 0.023). Similar results were found for IC90 with val-
ues above prior years in 55 and 23  % of isolates from 
recrudescent and non-recrudescent cases, respectively 
(χ2 = 8.51; P = 0.004).
Drug susceptibility profiles do not suggest cross‑resistance 
between PPQ and ARTs
To examine possible cross-resistance between PPQ and 
AS, 85 Cambodian isolates from 2014 to 2015 and 14 
northeastern Thai isolates from 2013 to 2014 were tested 
in the RSA to measure % survival rate against DHA, and 
their association with PPQ IC50 and IC90 was assessed. 
Survival rates for 72 evaluable Cambodian isolates 
ranged from 0 to 100 % with a median of 7.7 and IQR of 
2.0–16.4, while reference clone survival was as expected 
with medians of 0.3, 2.7, and 79.1  % for ART-sensitive 
W2, ART-resistant IPC-4884 and IPC-5202, respectively 
(Fig.  4). Based on an ART resistance cut-off above 1  % 
survival, only 22 % of Cambodian isolates (16/72) were 
sensitive to ARTs, while 78  % (56/72) were deemed 
resistant. No significant differences in the proportion 
of resistant isolates between 2014 (47/54  =  87  %) and 
2015 (13/18 =  72  %) were found (χ2 =  2.13, P  >  0.05), 
although there was a decrease in median survival rate for 
2015 isolates (9.6), compared to those from 2014 (4.8), 
Mann–Whitney test, P = 0.017. Median survival rate for 
western Thai isolates was 24.0 with an IQR of 4.7–48.6, 
nearly all (13/14) were resistant to ARTs with survival 
rate above 1  %. Due to limited data available for Thai-
land, the change in ART resistance over time was not 
evaluated.
There was not a significant correlation between % sur-
vival rate in the presence of ARTs and PPQ IC50 or IC90 
(Spearman ρ < 0.1, P > 0.05). ART-resistant Cambodian 
isolates (survival rate  >  1  %) had higher PPQ ICs than 
sensitive isolates (survival rate  ≤1  %), but differences 
were not statistically significant with IC50 of 448  nM 
for resistant isolates vs 268  nM for sensitive (P value 
for Mann–Whitney U test = 0.99), and IC90s of 9175 vs 
4489 nM, respectively (P = 0.84).
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Discussion
Monitoring ex  vivo drug susceptibility of P. falciparum 
revealed rapid progression of PPQ resistance in north-
ern Cambodia between 2013 and 2015, following reports 
of severe clinically significant resistance in 2013 [15, 
18], while western Thai isolates collected from the same 
time period remained sensitive to PPQ corresponding 
with a recent report of 94  % efficacy of DHA-PPQ in 
this region [5]. The northeastern Thai isolates showed 
modest worsening of PPQ resistance given their close 
proximity to the Cambodian parasite populations stud-
ied (within 100 km). Increased PPQ IC50 and IC90 asso-
ciated with recrudescence in DHA-PPQ clinical studies 
from 2010 to 2013 corresponded with the first reports of 
DHA-PPQ clinical treatment failures in Cambodia [18, 
19, 26]. The findings enforce those of recent studies, indi-
cating the rapid expansion of PPQ-resistant parasites in 
Cambodia, as well as early signs that piperaquine resist-
ance is emerging in Thailand. Given rapid emergence in 
Cambodia, and the fact that DHA-piperaquine has only 
recently been introduced on a large scale, the possibil-
ity for rapid worsening of resistance in Thailand is high. 
Limited treatment to choose from there is an urgent need 
for alternative therapies in the region. Whether the rapid 
expansion of PPQ resistance is due to increased trans-
mission potential of PPQ-resistant isolates as observed 
for ART-resistant parasites [6] or slow-clearing parasites 
following DHA-PPQ treatment [27], requires further 
investigation.
The majority of both Cambodian and Thai isolates were 
resistant to ARTs in a RSA, consistent with a high preva-
lence of mutations in the propeller domain of the P. falci-
parum kelch13 associated with ART resistance in nearly 
100  % of isolates [15]. This supports emerging PPQ 
resistance on an ART resistance background given the 
high rate of clinical DHA-PPQ failures [18, 26], although 
there was no clear cross-resistance between PPQ and 
the ARTs, in part given the very high rate of ex  vivo 
ART resistance. Similar to previous reports [15, 18, 26], 
the opposite trend was observed for MQ with increased 
ex  vivo sensitivity noted in Cambodian isolates from 
2013-2015. Studies also revealed the association of DHA-
PPQ treatment failure with single copy of P. falciparum 
multi-drug resistance gene (pfmdr1) and decreased MQ 
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Fig. 4 Ring-stage survival assay (RSA) for artemisinin susceptibility of Plasmodium falciparum isolates and reference clones. Black unfilled and filled 
circles represent  % survival rate in the ex vivo RSA for Cambodian isolates from Oddar MeanChey (OM) province and in vitro 0−3h RSA for Thai 
isolates from Pursaron (PL) village in Srisaket province, respectively. Blue squares denote values of ART-sensitive (W2) clones while triangles indicate 
ART-resistant clones (IPC-4884-purple and IPC-5202-green) obtained from 5 to 7 independent in vitro 0−3h RSA experiments. Bars represent median 
and interquartile range. Zero values of % survival rate were plotted as 0.001 % in logarithmic scale
(See figure on previous page.) 
Fig. 3 PPQ and MQ susceptibility of Cambodian and Thai isolates collected from 2010 to 2015. Panels a and b, respectively, present ex vivo P. 
falciparum IC50 and IC90 for PPQ, while MQ IC50 is shown in panel c. Site/year where samples were collected are indicated on the X-axis—Preah 
Vihear (PV), and Oddar MeanChey (OM) provinces of Cambodia, and Kwai River Christian Hospital (KRCH) in Kanchanaburi Province and Pursaron 
(PL) in Srisaket Province, Thailand, with median values of IC50 or IC90 denoted for each site/year with a black bar and indicated on X-axis. Red dotted 
lines indicate the PPQ susceptibility baseline of Cambodian isolates from 2010–2012 (a, b) and WHO values for suspected MQ resistance (c). The 
W2 susceptibility value is indicated by blue dashed lines. Isolates above prior year baseline for PPQ (IC50 > 69 nM, IC90 > 160 nM) are in red, with the 
proportion isolates above baseline indicated
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IC50. The concomitant increase in MQ sensitivity coupled 
with worsening PPQ resistance could be explained by 
declining PPQ susceptibility within parasite population, 
being genetically distinct from those of MQ resistance. A 
recent population genetics study revealed emergence of 
PPQ resistance related to clonal expansion of MQ-sen-
sitive parasites with a single pfmdr1 copy (Parobek et al. 
pers. comm.)
Ex vivo parasite susceptibility to PPQ, particularly 
the IC90, appears to be a sensitive, field-expedient and 
relatively cost-effective marker to detect emerging PPQ 
resistance at sentinel sites in high-risk areas. Surveillance 
data first revealed the occurrence of PPQ-resistant para-
sites in Cambodia in 2010, a year before the clinical failure 
rate of DHA-PPQ began to increase. Although isolates 
from 2010 largely remained in the IC50 susceptible range, 
elevated IC90 was detected in three isolates, two of which 
were in patients who failed DHA-PPQ treatment [28]. In 
2013 when clinical failure for DHA-PPQ was prevalent, 
IC90 was elevated in 40  % of isolates though more than 
half still had IC50 in the sensitive range. A rapid pro-
gression of resistance was detected in years following 
with rapid rises in both IC90 and IC50 for most isolates. 
Decreased parasite susceptibility to PPQ was associated 
with DHA-PPQ treatment failure, notably for IC90, which 
was three-fold higher in subjects failing treatment. IC90 
appeared to better elucidate shifts in resistance patterns 
over time and their association with treatment outcomes 
compared to IC50. Anomalous curves observed with 
PPQ-resistant isolates in the HRP-2 assay required PPQ 
concentrations up to 53,905 nM (>25 times higher than 
the maximum concentration used by Duru et  al. [26] 
before 100  % growth inhibition producing an interpret-
able, sigmoidal, dose–response curve could be achieved 
(Fig.  2). Similar to findings with HRP-2, a recent study 
reported poor performance of the standard hypoxanthine 
uptake assay due to the high frequency of non-interpret-
able curves observed with PPQ-resistant isolates. The 
anomalous curves produced suggested a paradoxical 
increase in parasite growth at PPQ concentrations above 
100–200 nM, reflecting a resistance mechanism induced 
at physiological concentrations (~200  nM) observed in 
the blood of patients treated with DHA-PPQ [26, 29]. 
Evidence of paradoxical growth at high concentrations of 
drugs was previously described in non-ART drug assays 
[30]. This was suggested to reflect biological properties 
of drugs, including mechanism of action. Amendment of 
the lower constraint of the sigmoid model was suggested 
to provide a more accurate measurement. However, this 
is not the case for the paradoxical growth seen among 
resistant isolates in the PPQ assay demonstrated here, or 
in another recent report [26], and may represent a phe-
nomenon of PPQ-resistant isolates.
To compensate for these challenges for interpretation, a 
novel in vitro assay for PPQ resistance, the PPQ survival 
assay (PSA), was designed to mimic in vivo exposure of 
parasites to a pharmacologically relevant dose of PPQ 
(200 nM) for 48 h with the  % parasite survival rate meas-
ured at 24 h after drug exposure [18, 21, 26]. A 48-h drug 
incubation period allows adequate PPQ exposure for all 
parasite stages from 0-h rings to 48-h schizonts, given 
PPQs having long clinical half-life (~9 days) [26, 29]. As a 
result, the assay does not assess parasite susceptibility to 
PPQ at a specific parasite stage, but rather the entire life 
cycle. PSA was demonstrated to be a useful tool to dif-
ferentiate PPQ resistance among individual fresh isolates, 
and the % survival rate was found to correlate with DHA-
PPQ treatment outcome. Future investigations employ-
ing this method are likely to further elucidate emerging 
piperaquine resistance, although the requirement for 
multiple individual microscopy readings on each sam-
ple limits assay throughput to some degree. The choice 
of method (PSA, HRP-2, etc.) should be based on avail-
able resources and experience. In our view, consistency of 
application, reproducibility and interpretability of results 
across time and place are far more important than the 
technique selected.
The limited sample size for Thai isolates, as well as 
lack of more recently collected samples are important 
limitations of the current study. This was mitigated by 
the sequential approach employed at the sentinel sites, 
increasing the degree of confidence that median values 
presented here were reflective of relative drug sensi-
tivities at the community level. Isolates from the Thai–
Myanmar border remained highly sensitive to PPQ 
despite ART resistance comparable to the levels seen in 
Cambodia, as well as modest MQ resistance. Samples 
were collected before the widespread use of PPQ in Thai-
land when AS-MQ remained the first-line drug. While 
there has clearly been rapid expansion of resistance in 
northern Cambodia, there appears to be only limited 
spread across the Thai border, with isolates from nearby 
PL, Thailand having only moderate declines in PPQ sus-
ceptibility. This may be due in part to a lower burden of 
disease in northeastern Thailand permitting more strin-
gent control measures, and anti-malarial drug admin-
istration limited to well-resourced government public 
health clinics. Regardless, ongoing monitoring is impera-
tive in this region.
Several reports have suggested that ART resistance 
could promote development of resistance to PPQ, as 
ART-resistant isolates surviving in the presence of ACT 
are more likely to spontaneously develop resistance to 
partner drugs [18, 21]. The association between PPQ 
resistance and the K13 mutation likely reflects selection 
of PPQ-resistant parasites as those initially resistant to 
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ARTs remain viable well after ACT treatment has been 
completed. This has been supported by apparent corre-
lations between increasing DHA-PPQ failure rates on a 
background of ART-resistant isolates with K13 mutations 
[17–19]. A recent study reported that all PPQ-resistant 
isolates carried the K13 mutation, although direct cor-
relation between PPQ and ART susceptibility was not 
clear as PPQ-sensitive isolates also carried K13 mutation 
[26]. This may be due to the high prevalence of K13 in the 
parasite populations studied, and limits potential analysis 
within the present dataset. Cutoff IC50 or IC90 values for 
PPQ resistance have yet to be defined, we have not made 
an effort here to compare % survival rate to ART between 
PPQ ‘resistant’ and ‘sensitive’ isolates. We performed a 
Spearman correlation analysis between % survival rate 
and PPQ IC50 or IC90 and also compared PPQ IC50/IC90 
between ART-sensitive (RSA ≤ 1 %) and resistant isolates 
(RSA > 1 %). A significant correlation between ART and 
PPQ resistance was not found (see Additional file 1).
Making use of these data for public health purposes 
presents important challenges, although there does 
appear to be a key opportunity in the inverse resistance 
pattern between PPQ and MQ. PPQ resistance appears 
to be developing in MQ-sensitive parasites with single-
copy Pfmdr-1 and low MQ IC50, as PPQ-resistant iso-
lates in a recent study (PSA survival rates ≥10 %) all had 
a single Pfmdr-1 copy and were largely MQ sensitive [26]. 
Correspondingly, a parasite population genetics study 
identified the development of resistance to PPQ and MQ 
in genetically distinct parasite populations (Parobek et al. 
pers. comm.). In the interim, the national control pro-
gramme in Cambodia has reverted to the re-introduc-
tion of AS-MQ ACT in selected areas of PPQ resistance, 
and previous studies have observed excellent cure rates 
using AS-MQ as rescue therapy for DHA-PPQ treat-
ment failures [17, 28]. Recent investigations have pro-
posed triple-drug therapy such as simultaneous AS, MQ 
and PPQ [18], although the safety of such combinations 
has not been studied. Further, the possibility of inducing 
simultaneous resistance to all three drugs amidst rising 
resistance to the individual components would argue for 
preserving the advantages afforded by inverse MQ and 
PPQ resistance patterns by rotating two drug ACT com-
binations sequentially, combined with inpatient follow-
up of all cases to ensure compliance [21]. Doing so in a 
carefully coordinated fashion on a biannual basis would 
permit adequate time to restore at least partial part-
ner drug sensitivity, while holding the current second-
line therapy in reserve for clinical treatment failures. 
Atovaquone-proguanil used as part of public health con-
tainment activities in Cambodia may prove to be a use-
ful albeit costly third-line agent, as isolates from the same 
areas of PPQ resistance in northern Cambodia reported 
here were recently shown to remain highly susceptible to 
atovaquone (ATQ) in vitro without evidence of pre-treat-
ment mutations in the cytochrome b gene codon 268 
marker for ATQ resistance [24]. However, this liability is 
well known, with several studies reporting rapid develop-
ment of single point mutations in cytochrome b confer-
ring ATQ resistance during treatment [31–33]. Neither 
approach will adequately address the current high-grade 
ART resistance in the region, although there is hope they 
may extend the life of current ACT until novel com-
pounds in development, such as the spiroindolones [34] 
and synthetic ozonides [35], become available.
Conclusions
The study revealed the rapid expansion of PPQ-resist-
ant parasites in northern Cambodia during 2013–2015, 
while Thai isolates remained sensitive to PPQ, or showed 
modest worsening of resistance for those in close prox-
imity to the Cambodian study sites. The opposite trend 
was observed for MQ with increased ex vivo sensitivity 
noted in Cambodia. Rapid progression of PPQ resistance 
associated with the treatment failures of the latest ACT 
regimen, DHA-PPQ, in northern Cambodia. The find-
ings enforce those of recent studies, indicating the rapid 
expansion of PPQ-resistant parasites in Cambodia, as 
well as early signs that piperaquine resistance is emerg-
ing in Thailand. Limited drugs of choice in this region 
highlights the demand alternative therapies. While the 
re-introduction of AS-MQ ACT remained a treatment 
choice for PPQ-resistance areas at time of writing, care-
ful monitoring for re-emergence of MQ resistance and/
or simultaneous resistance to all three drugs (AS, MQ 
and PPQ), as well as of the spread of PPQ resistance to 
nearby countries, remain crucial to address the resist-
ance crisis.
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